Page 10 - End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

European Commission Approves Pfizer s ELREXFIO for Relapsed and Refractory Multiple Myeloma

08.12.2023 - Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory .

United kingdomAl hamedExchange commissionApproval programDrug administrationEuropean commissionNational cancer instituteMyeloma research foundationWorld health organizationEnd results programHealthcare products regulatory agencyEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useAccelerated approval program

RedHill Biopharma Announces FDA Grant of 5-Year U S Market Exclusivity for Talicia® with IP Protection Running to 2034

RedHill Biopharma Announces FDA Grant of 5-Year U S Market Exclusivity for Talicia® with IP Protection Running to 2034
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAdi frishPatricia andersonRedhill biopharmaRegulatory affairsCompany annual report on formNational cancer institutePrnewswire redhill biopharma ltdDrug administrationRedhill biopharma ltdCorporate business developmentWorld health organizationEnd results programCompany expanded access programExchange commission

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBrendan mcevoyDaiichi sankyoDave fredricksonKomal jhaveriJillian gonzalesMemorial sloan kettering cancer centerCancer research technologyNational comprehensive cancer networkInstitute of cancer researchEuropean unionEnd results programMerck co incAmerican cancer societyDrug administration

AstraZeneca s Truqap approved in the US for HR-positive breast cancer

AstraZeneca's Truqap approved in the US for HR-positive breast cancer

United kingdomDave fredricksonAstrazeneca truqapKomal jhaveriDrug administrationNational cancer instituteEuropean unionEnd results programMemorial sloan kettering cancer centerNew england journalMedical oncologistExecutive vice presidentOncology business unitPriority reviewProject orbisAstex therapeutics

Cancer Costs Conversations Are Important, But Underutilized

Most patients with cancer may not be discussing the cost of care with their clinicians, according to recent research.

United statesVeena shankaranRobin yabroffHutchinson institute for cancer outcomes researchEnd results programFred hutchinson cancer centerAmerican cancer societyFinancial toxicityHutchinson instituteCancer outcomes researchFinancial issues